call XXXX to and morning, I'm is Titan and excited today very Officer. me you, financial Stephen join the on welcome quarter President CEO. Titan to Thank call. our Lemieux, Financial Also Kristen. Chief joining update second Medical’s Good as
September to surgical CEO XXXX. the company two Directors I why the of in sadistically I've why commitment mission joined for is As last years this space That Titan’s strong have been a and month. improve as , Board passion outcomes. member joined joined nearly ago I company's many is that a since board of I of the to
the for so Titan system. today's On and the the surgery space. And my or want past opportunity stronger. Over built been Titan company's I month robotic the into in prospects have innovation the assisted in belief we to the see never Enos that review future for call
single and XXX over in surgery including articulating provides change coverage access controllers. portfolio aspects dexterous belief for the entrants covering positive robotic highly to high-definition wraps, property breadth an patients, our and patents tighten of Medical includes ways. of surgery in applications. paradigm as depth with and and in instruments, families the and from newer in coverage surgeon apart dates vision hand Specifically, This single early that the access innovation robotic patent systems of RAS. intellectual innovative, advanced or RAS Patents technological novel leader assisted ergonomic surgical our surgical technology surgeons ability hospitals in Head with
and potentially licensing additional scars, body. provides potential the less benefits and points, was designed opportunities. Importantly, resulting to first patients The smaller with pain or commercial of system potential in improve the with portfolio and the our trauma access faster outcomes valuable restoring gains defense recovery the IP technologies, and incisions to competitive including company by fewer reducing for number Enos and from protection
ease of efficiency systems to room to the operate effective with We and And team. promoting more the for and openly surgeon comfortable for enables the more surgeons. ergonomic by for operating footprint drive surgeries. required at communication easier, procedures adoption the between the third, costs, know decreasing surgical hospitals interact increase lowering making Second, team the surgical workstation members equipment
system Our our with surgical XD order account card The XD in XD addition designed and a patient no XD an articulating two designed interacted in easy and meets with movements. has taken camera that dexterous overlays. preferences patient that or of system volume, those card. that in as HD easy interface incision. convert and camera HD technology have close to for screen and from system's received their In needs. foot graphical pedals displaying the We is integrated required a the accurate wall the repeatedly a operate system versatility camera reposition into precision the single dexterous allow prototypes heard the surgical consists increased master. feedback steerable endoscope to including entry images have and and learn designed to system, deliver is and to of abdominal to point surgeon to instruments site and XX-millimeter learn, instruments in into through well Titan Enos multi a when natural without the surgical we extendable surgeons, to Furthermore, to controllers surgeons tight hand cam these designing and having with gestures of illumination HD the to Enos additional instruments illumination HD as
features to to these We cart suite The and over turn to multi the the is allow load multi-port offer efficiently. market Additionally, Currently believe faster surgical grow. to to instruments and continues RAS market patient swift dominated draping. systems. quadrant designed is and by will easy more is surgical hospitals docking, the systems positioning, easy robust
Enos such a more for rest access market our research as is of innovative market. current the small, the While suggests somewhat exists segment the opportunity overall comprise significant access systems to an single that an system single systems for
Based a Enos believe and may needs. conducted future current capabilities data critical a enhance collected single the using Pathway applications most impactful. address Innovation in gynecology, studies we Enos follow to appropriate other range leading of surgeries. procedures system to system, Surgeon's Their of meetings access this for what wide for preclinical to that range colorectal for and with Board, also of indication for intend clearance gained a regulatory the general and looking part which continues clearances for system likely be the regulatory procedures Enos on to generation and Advisory insight of intake for Enos the of initial might intend data, surgeons roadmap system, procedures. our eventually including for can be be are and we've We are used the next indications launch with a with how by the needs, we Upon only During of access we surgical the gynecology that to surgeons support the influence benefits of system surgery several Enos urology, will provide on robotics. in meet unmet use. of members but valuable In surgical added technology single our not be urology the
rings is Although in to one and committed plan, project to The proprietary benefit patients. challenges it the surgeons is overcome creatively team to hands at early our working to days theme clear. Titan technology of for me tirelessly our get
that We accomplish have and market. get the partners authorized in We who value be collaborating contributors our our with are the to fortunate to as those role success appreciate share the we on system our collaborations all and in goals. Enos mission
XXX-day the And quarter the several Titan minimum address compliance accomplishments deficiency to In to extension the evaluate we NASDAQ XX, shared price during rule. weeks to we'll deadlines. addition and with regain my options XXXX regain to has price compliance December by second bid recent an including were following, continue announcements, to additional to prior granted the
for to ongoing utilizing plan We a process as obtain part Enos additional the of FDA continued communications clinical our Q-Submission the submission regarding FDA, Novo system. the with guidance from the De
and hear of of Meeting, and the shareholders. as Manufacturing by an in directors of Marketing Seibert, development share We share Medical. Robotic Engineering clinical Vice He robotic year. Surgery an Enos for relationships. as President, him the Annual of their panel from skew and manufacturing will responsible technology contract for Enos Chris to companies as validation Titan on our company continues transfers nominees team expect preclinical half access in are Fahey Enos were shareholders employee system manufacture single this held be the FDA capital expected card. and We're consumables. SVP at the to experience in all VP Spine the The verification testing, the share Society later Discussion as the manufacturing of the the Blackstone this to of on X, executives board Medical benchmark back on for featuring Enos participated Annual of studies of the Upstream the XXXX welcome including system. the surgeon in amendment of the as unit units Shareholders participated Engineering of June We both previously Enos provided Special The for in submission recognized from system surgery. adoption of and Bill brings workstation during single tightening in He path the approved served house Bill Operations. the company promising used platforms overview a surgical of and for design for and elected and the and Senior Manufacturing we excited purchase Netia also agreement finalize surgical commercialization have Technologies We We We Meeting will system, robotic an Director on of announced plenary be and plan components plan surgical plan. of with Precision components These use second patient Orthotics session. year. to manufacturing and unit to the deferred renewal the
Investment met is encourage We Finally, investors. listen our and HC we Conference webcast May with website. participated the on on Wainwright the you available Global in in XX, to Miami which to
instruments for process. we FDA validation classification for announced be quarter mid-XXXX, year. turn first communications disruptions multiple constructive. the supply in versus expected utilizing components June XX, we are materials and submission proceeding the key and We affect plans request would would of of pathway authorization an verification result that which the in in On IDE De previously noted communicated, marketing Novo the delays certain next to testing with with continues production As our cameras, of
unit and engineers resourcing and developers delays recruitment and testing documentation. slow of Additionally, software
of Finally, to to year. cleaning these early at our With anticipated scheduled clinical we the XXXX. of plan on four Novo in IDE De marketing XXXX. clinical issues, study. begin study, to disinfecting upon the during testing we system on to with trials perform and Enos FDA the sites a delayed expect eye planning postponed request for GLP clinical is hysterectomy FDA laparoscopic consumable the a the classification of submit We're IDE in procurement watchful patients approximately Upon submission. of XX clinical from components and the our authorization next start total human disposable three receipt study completion launch to the Commercial required and
on execute project and monitor carefully to our plan. continue will We
and instability, Additionally, we conflict, COVID economic supply mitigate ongoing labor risk market, chain variants, to and impact issues market Ukraine-Russia we including are tightening monitoring the geopolitical where and are anticipate able. trying a factors in
to our continue intellectual We property will grow portfolio.
and team knowledge company and within and the Our position our experience to strengthen talented the our promote industry.
product Lemieux, exciting the Enos on shareholders, others for the We will improving media the share outcomes, plan and received and our leverage a I'm turn for in Titan’s look to and shareholders. with surgical benefits Officer be our positively is Stephen? Financial meaningful impact to Enos and of to FDA, robotic access we our the to and surgeons will narrative developing improve multiple audiences positioned Enos at technology. to to the provide hospitals. industry our differentiated believe assisted members system effect to and our strongly hospital engage I system We company when prospects to the optimistic how excited surgery will with to outcomes. remain that to financial intend it we for physicians, we the assisted our Stephen we opportunity call of results. as that uniquely believe cleared by platform, by access to Additionally, well the surgical review economics. believe partnerships patient provide innovative meet the robotic single make Chief continue share single We improvements long-term will performance surgeons system have now
